Cargando…

Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study

BACKGROUND: Apatinib is an oral anti‐angiogenic drug, its efficacy and prognosis in cervical carcinoma are unclear. This study evaluates the effectiveness and prognostic factors of apatinib in the treatment of recurrent or advanced cervical carcinoma. METHODS: Patients with recurrent or advanced cer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Hui, Chen, Min, Mei, Zijie, Xie, Conghua, Zhou, Yunfeng, Qiu, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267132/ https://www.ncbi.nlm.nih.gov/pubmed/33987959 http://dx.doi.org/10.1002/cam4.3966

Ejemplares similares

A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy
por: Yang, Hui, et al.
Publicado: (2021)

Effectiveness and safety of low‐dose apatinib in advanced gastric cancer: A real‐world study
por: Du, Yingying, et al.
Publicado: (2020)

Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer‐bearing mice and patients
por: Liu, Mingtao, et al.
Publicado: (2020)

Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma
por: Yang, Chaoxu, et al.
Publicado: (2018)

Construction and validation of a prognostic nomogram for anal squamous cell carcinoma
por: Yang, Ningning, et al.
Publicado: (2021)

Combining pretreatment plasma Epstein‐Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study
por: Du, Yu‐Yun, et al.
Publicado: (2019)

Efficacy and safety of low‐dose apatinib in ovarian cancer patients with platinum‐resistance or platinum‐refractoriness: A single‐center retrospective study
por: Chen, Wei, et al.
Publicado: (2020)

Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancer
por: Li, Jing, et al.
Publicado: (2016)

Combined prognostic value of pretreatment anemia and cervical node necrosis in patients with nasopharyngeal carcinoma receiving intensity‐modulated radiotherapy: A large‐scale retrospective study
por: Zhang, Lu‐Lu, et al.
Publicado: (2017)

Prognostic value of MRI‐determined cervical lymph node size in nasopharyngeal carcinoma
por: Huang, Cheng‐Long, et al.
Publicado: (2020)

Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial
por: Zhou, Jian-Guo, et al.
Publicado: (2018)

Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial
por: Mei, Kuimin, et al.
Publicado: (2021)

D2‐resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy
por: Peng, Jin, et al.
Publicado: (2016)

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
por: Liu, Jieqiong, et al.
Publicado: (2020)

The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study
por: Yu, Jiangtao, et al.
Publicado: (2019)

Survival and prognostic factors of patients with esophageal fistula in advanced esophageal squamous cell carcinoma
por: Guan, Xin, et al.
Publicado: (2020)

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
por: Yuan, Shumin, et al.
Publicado: (2022)

Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma
por: Liang, Yuelong, et al.
Publicado: (2017)

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
por: Xia, Yongxiang, et al.
Publicado: (2022)

The impact of bone marrow irradiation dose on acute haematologic toxicity in cervical cancer patients treated with concurrent chemoradiotherapy
por: Chen, Min, et al.
Publicado: (2023)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Poor prognostic and staging value of tumor deposit in locally advanced rectal cancer with neoadjuvant chemoradiotherapy
por: Wang, Yaqi, et al.
Publicado: (2019)

A retrospective six-patient series of apatinib for the treatment of persistent or recurrent carcinoma of the cervix
por: Chen, Chao, et al.
Publicado: (2019)

Development and validation of a prognostic nomogram for ambulatory patients with advanced cancer
por: Paiva, Carlos Eduardo, et al.
Publicado: (2018)

Cervical lymph node carcinoma metastasis from unknown primary site: a retrospective analysis of 154 patients
por: Wang, Yan, et al.
Publicado: (2018)

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
por: Xie, Lu, et al.
Publicado: (2020)

Apatinib is effective for treatment of advanced hepatocellular carcinoma
por: Kong, Yinlong, et al.
Publicado: (2017)

Apatinib as an alternative therapy for advanced hepatocellular carcinoma
por: Zhang, Xi-Hao, et al.
Publicado: (2020)

Clinical characteristics and prognostic value of pre‐retreatment plasma epstein‐barr virus DNA in locoregional recurrent nasopharyngeal carcinoma
por: Liu, Ming‐Zhu, et al.
Publicado: (2019)

Application of a novel prognostic invasive lesion index in ductal carcinoma in situ with minimal invasion of the breast
por: He, Xiaofang, et al.
Publicado: (2017)

Treatment optimization for recurrent hepatocellular carcinoma: Repeat hepatic resection versus radiofrequency ablation
por: Lu, Liang‐He, et al.
Publicado: (2020)

The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma
por: Hu, Lijun, et al.
Publicado: (2020)

Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy
por: Chen, Hai‐Long, et al.
Publicado: (2018)

The Selection of Time Interval Between Surgery and Adjuvant Therapy in Early Stage Cervical Cancer
por: You, Kai-Yun, et al.
Publicado: (2018)

Value of radiotherapy in addition to esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma: Analysis of surveillance, epidemiology, and end results database
por: Yu, Jing, et al.
Publicado: (2018)

Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients
por: Chen, Chang-Zhi, et al.
Publicado: (2021)

The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study
por: Nie, Caiyun, et al.
Publicado: (2021)

Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients
por: Huang, Da, et al.
Publicado: (2022)

Prognostic values of the clinicopathological characteristics and survival outcomes in micropapillary urothelial carcinoma of the bladder: A SEER database analysis
por: Jin, Di, et al.
Publicado: (2020)

Late rectal toxicity determined by dose–volume parameters in computed tomography‐based brachytherapy for locally advanced cervical cancer
por: Zhou, Yong‐Chun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hmpv8otd5btlps61o9dbsvgcn9